Quick Facts

• Dopamine levels in the brain’s memory center drop to less than one-fifth of normal in Alzheimer’s patients
• Levodopa, a Parkinson’s drug, restored memory function in mice and could offer immediate clinical trial potential
• The discovery shifts focus from removing brain plaques to restoring memory circuit function

University of California, Irvine researchers have identified dopamine dysfunction in the entorhinal cortex as a key driver of memory loss in Alzheimer’s disease. The study, published in Nature Neuroscience, reveals for the first time how dopamine deficiency directly contributes to impaired memory formation.

The research team found dramatic dopamine reductions in the entorhinal cortex, a brain region that connects the hippocampus and neocortex and serves as critical infrastructure for memory formation. In mouse models of Alzheimer’s, dopamine levels dropped to less than one-fifth of normal levels.

“We did not initially expect dopamine to be affected in Alzheimer’s disease,” said lead researcher Dr. Kei Igarashi. “However, as the evidence accumulated, it became clear that dopamine dysfunction plays a central role in memory impairment.”

When researchers restored dopamine levels using optogenetic techniques, the mice regained their ability to form memories. More significantly, administration of Levodopa, a drug widely used to treat Parkinson’s disease, also normalized neural activity and improved memory performance.

The findings represent a shift from current Alzheimer’s treatments that focus on removing toxic proteins like amyloid-beta and tau. Those approaches often fail to restore memory once neuronal dysfunction occurs.

Separate research from Japan’s RIKEN Center for Brain Science found another dopamine pathway for fighting Alzheimer’s. The team discovered dopamine promotes production of neprilysin, an enzyme that breaks down harmful brain plaques.

“We have shown that L-DOPA treatment can help reduce harmful beta-amyloid plaques and improve memory function in a mouse model of Alzheimer’s disease,” said study author Watamura Naoto.

The research carries immediate clinical potential because Levodopa is already FDA-approved and widely prescribed for Parkinson’s patients. This opens a direct path for clinical trials testing whether the drug can slow or reverse early memory loss in human Alzheimer’s patients.

An estimated 6.9 million Americans age 65 and older live with Alzheimer’s dementia. Without medical breakthroughs, this number could reach 13.8 million by 2060, according to the Alzheimer’s Association.

The entorhinal cortex shows the earliest damage in Alzheimer’s disease, making it a logical target for intervention. The region’s role in connecting different brain areas makes it essential for associative memory, which declines early in the disease.

Read more: Research Finds This Dysfunction Could Be Fueling Alzheimer’s Risk